Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.
The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell ...
US pharma major Merck (NYSE: MRK) has reported a Phase III success for Welireg (belzutifan) plus Keytruda (pembrolizumab) as ...
In the absence of trials, a post hoc analysis compared stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy (HDR-BT) in intermediate-risk prostate cancer.
Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...
A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive ...
A large national study in Denmark following nearly 1,900 patients over almost a decade has found that a minimally invasive ...
Learn about the innovative SHIELD blood test by Guardant Health that aims to detect colorectal cancer early, potentially revolutionizing cancer screening methods. Discover its availability, impact, ...
Chronic kidney disease is a silent epidemic that is often diagnosed too late, leading to limited treatment options and poor outcomes, and the U.S. health care system needs to prioritize early ...
A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive procedure ...
Chronic kidney disease is a silent epidemic that is often diagnosed too late, leading to limited treatment options and poor ...
I revved up my longevity protocols and sought out the latest predictive screenings. Was I seizing control of my health or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results